A validated ultra-performance liquid chromatography-tandem mass spectrometry method for the quantification of polymyxin B in mouse serum and epithelial lining fluid: application to pharmacokinetic studies
Open Access
- 22 January 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 68 (5) , 1104-1110
Abstract
A rapid, sensitive and robust ultra-performance liquid chromatography–tandem mass spectrometry (UPLC-MS/MS) method was developed for the quantification of four major polymyxin B components (polymyxin B1, polymyxin B2, polymyxin B3 and isoleucine-polymyxin B1) in serum and epithelial lining fluid (ELF) samples. A Waters Acquity UPLC HSS C18 column was used with 0.1% formic acid in water/acetonitrile as mobile phases. Analysis was performed in a positive ionization mode with multiple-reactions monitoring scan type. Five percent trichloroacetic acid was used to precipitate proteins in biological samples and to increase the sensitivity of detection. Our results showed a linear concentration range of 0.0065–3.2 mg/L for all the major polymyxin B components in both serum and ELF, respectively; the interday variation was <10% and the accuracy was 88%–115%. The validated method was used to characterize the pharmacokinetics (serum and ELF) of polymyxin B in mice. This is the first report, to date, examining the individual pharmacokinetics of various polymyxin B components in mice. Our results revealed no considerable differences in clearances among the components. The limited exposure of polymyxin B in ELF observed was consistent with the less favourable efficacy of polymyxin B reported for the treatment of pulmonary infections. This method can be used to further examine the pharmacokinetics of polymyxin B in a variety of clinical and experimental settings.Keywords
This publication has 17 references indexed in Scilit:
- In Vitro Potency of Various Polymyxin B ComponentsAntimicrobial Agents and Chemotherapy, 2011
- LC–MS/MS method development and validation for the determination of polymyxins and vancomycin in rat plasmaJournal of Chromatography B, 2010
- Variability of polymyxin B major components in commercial formulationsInternational Journal of Antimicrobial Agents, 2010
- Interpretation of Antibiotic Concentration Ratios Measured in Epithelial Lining FluidAntimicrobial Agents and Chemotherapy, 2008
- Intravenous polymyxin B for the treatment of nosocomial pneumonia caused by multidrug-resistant Pseudomonas aeruginosaInternational Journal of Antimicrobial Agents, 2007
- Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001–2004)Clinical Microbiology and Infection, 2006
- Pharmacodynamics of Polymyxin B against Pseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 2005
- Multidrug-resistant Pseudomonas aeruginosa in Brooklyn, New York: molecular epidemiology and in vitro activity of polymyxin BEuropean Journal of Clinical Microbiology & Infectious Diseases, 2005
- Isolation and structural characterization of polymyxin B componentsJournal of Chromatography A, 2001
- Liquid chromatography of polymyxin B sulphateJournal of Chromatography A, 2000